Interestingly, previous studies utilized CEACAM6-targeted antibodies to deliver anticancer drugs such as maytansinoid (DM1) [60] and gemcitabine [61] for PDAC therapy or to deliver doxorubicin in NSCLC [62] and paclitaxel [61] in lung cancer. Here, CEACAM6 is linked to non-small cell lung carcinoma.